JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Original Article
Neutrophil-to-lymphocyte ratio as a predictor of progression in patients with early-stage cervical cancer
Aims: The neutrophil-to-lymphocyte ratio (NLR) has shown promise as a prognostic marker in various cancers, but its role in early-stage cervical cancer is not well defined. This study evaluates the association between pre-treatment NLR and progression risk in patients with early-stage cervical cancer.
Methods: This retrospective study included 220 patients with stage I and II cervical cancer treated from 2010 to 2024. Patients with prior treatment, infection at diagnosis, or hematological diseases were excluded. Pre-treatment NLR was calculated from blood counts taken within a week before treatment. Primary outcome was progression-free survival (PFS). Cox regression analyses identified prognostic factors.
Results: The median follow-up was 46 months (range, 1-120). Disease progression occurred in 17.3% of patients, and 15% died. The 5-year overall survival and PFS rates were 84.8% (95% CI: 79.3-90.3) and 77.7% (95% CI: 71.4-84), respectively. Univariate analysis identified non-squamous cell carcinoma (non-SCC) histology, tumor size >4 cm, and elevated NLR as significant factors affecting PFS. Multivariate analysis confirmed non-SCC histology (HR: 3.2, p=0.002), tumor size >4 cm (HR: 2.3, p=0.007), and elevated NLR (HR: 1.1, p=0.041) as independent PFS risk factors. Higher NLR correlated with larger tumor size.
Conclusion: Elevated pre-treatment NLR independently predicts disease progression in early-stage cervical cancer. Incorporating NLR into risk stratification could enhance prognostic assessments and guide personalized treatments. Larger prospective studies are needed for validation.


1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J Clin</em>. 2021;71(3):209-249.
2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. <em>CA Cancer J Clin.</em> 2024;74(1):12-49.
3. Hsieh HY, Lu CH, Wang L. Long-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage &ldquo;bulky&rdquo; cervical cancer and survival impact of histological subtype. <em>J Formos Med Assoc.</em> 2023;122(3):221-229.
4. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. <em>Clin Chim Acta.</em> 2015;445(12):7-11.
5. Yadav G, Srinivasan G, Jain A. Cervical cancer: novel treatment strategies offer renewed optimism. <em>Pathol Res Pract.</em> 2024;254 (15):155136.
6. Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. <em>Trends Cancer</em>. 2022;8(11):901-914.
7. Davidson B, Goldberg I, Kopolovic J. Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. <em>Pathol Res Pract</em>. 1997;193(7):491-495.
8. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <em>J Natl Cancer Inst.</em> 2014;106(6):124.
9. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. <em>Bratisl Lek Listy.</em> 2021;122(7):474-488.
10. Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. <em>BMC Med.</em> 2020;18(1):360.
11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. <em>Cell.</em> 2010;140(6):883-899.
12. Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as corrupted policemen in cancer-related inflammation. <em>Adv Cancer Res.</em> 2015;128(1):141-171.
13. Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. <em>J Hematol Oncol.</em> 2021;14(1):173.
14. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. <em>Proc Natl Acad Sci USA.</em> 2007;104(51):20262-20267.
15. Ethier JL, Desautels DN, Templeton AJ, et al. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <em>Gynecol Oncol.</em> 2017;145(3):584-594.
16. Zou P, Yang E, Li Z. Neutrophil-to-lymphocyte ratio is an independent predictor for survival outcomes in cervical cancer: a systematic review and meta-analysis. <em>Sci Rep.</em> 2020;10(1):21917.
17. Trinh H, Dzul SP, Hyder J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). <em>Clin Chim Acta. </em>2020;510(1):711-716.
18. Du JQ, Zhang F, Wang CQ, et al. Effects of peripheral blood neutrophil/lymphocyte ratio levels and their changes on the prognosis of patients with early cervical cancer. <em>Front Oncol. </em>2023;13(1):1139809.
19. Prabawa IPY, Bhargah A, Liwang F, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. <em>Asian Pac J Cancer Prev.</em> 2019;20(3):863-868.
Volume 5, Issue 4, 2024
Page : 203-207
_Footer